You are here:

Forthcoming Submissions:

PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
daratumumab (Darzalex) Janssen-Cilag Ltd Resubmission 31/07/2017 5/09/2017 9/10/2017
nivolumab (Opdivo) SCCHN Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 5/06/2017 1/08/2017 11/09/2017
nivolumab (Opdivo) UC Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 2/10/2017 Q4 2017 Q4 2018
obinutuzumab (Gazyvaro) FL Roche Full submission 2/10/2017 Q4 2017 Q4 2018
olaratumab (Lartruvo) Eli Lilly and Company Ltd Full submission 31/07/2017 3/10/2017 13/11/2017
palbociclib (Ibrance) Pfizer Ltd Full submission 4/09/2017 Q4 2017 Q4 2017
pembrolizumab (Keytruda) UC MSD Full submission TBC Q4 2018 Q4 2018
ribociclib (Kisquali) Novartis Pharmaceuticals UK Ltd Full submission TBC TBC TBC

Non-PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due

Medicines with advice withheld pending product availability

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due

Back